论文部分内容阅读
目的探讨血脂康在降低血脂正常脑梗死患者不良心脑血管事件中的效果。方法将2010年1-12月300例血脂正常的脑梗死患者随机分为A组(常规干预组)、B组(阿托伐他汀组)和C组(血脂康组)各100例,比较三组患者不良心脑血管事件发生率、不良反应发生率及干预前后的颈动脉内膜中层厚度、血清CK、CK-MB及AST、ALT。结果 B组与C组的不良心脑血管事件发生率均低于A组,干预后的血清CK、CK-MB低于A组,颈动脉内膜中层厚度优于A组,且C组不良反应发生率低于B组,P均<0.05,均有显著差异,而三组干预前后的血清AST与ALT均无显著性差异,P均>0.05。结论血脂康在降低血脂正常脑梗死患者不良心脑血管事件中的效果较好,可有效降低血管风险程度。
Objective To investigate the effect of Xuezhikang in reducing adverse cardiovascular and cerebrovascular events in patients with normal blood lipids. Methods 300 cases of normal blood lipids from January 2010 to December 2010 were randomly divided into group A (conventional intervention group), group B (atorvastatin group) and group C (Xuezhikang group) The incidence of adverse cardiovascular and cerebrovascular events, the incidence of adverse reactions and carotid artery intima-media thickness before and after intervention, serum CK, CK-MB, AST, ALT. Results The incidences of adverse cardiovascular and cerebrovascular events in group B and group C were lower than those in group A, but CK and CK-MB in serum were lower in group B than those in group A. Carotid artery intima-media thickness was superior to group A, and group C adverse reactions The incidence was lower than that in group B (P <0.05). There was no significant difference in serum AST and ALT before and after the intervention (P> 0.05). Conclusion Xuezhikang is effective in reducing adverse cardiovascular and cerebrovascular events in patients with normal blood lipids, which can effectively reduce the risk of vascular disease.